The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.
Offering an ultrasound platform that may have the capability to upgrade two-dimensional (2D) ultrasound devices with access to three-dimensional (3D) views of thyroid conditions, the Piur tUS Infinity system has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The Piur tUS Infinity platform enables clinicians to obtain multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity.
The newly FDA-cleared Piur tUS Infinity platform enables clinicians to obtain 3D multiplanar reconstructions from a single sweep with a traditional 2D ultrasound device, according to Piur Imaging, the developer of Piur tUS Infinity. (Image courtesy of Piur Imaging.)
Providing detailed volumetric assessment of thyroid lobes and nodules with a single scan, Piur Imaging said the Piur tUS Infinity platform facilitates nodule classification with the Thyroid Imaging Reporting and Data System (TI-RADS). The company added that the Piur tUS Infinity platform facilitates standardized reporting for PACS systems, and use of the 3D system may be reimbursed via CPT Category I code 76377.
“This technology offers an enhanced view into thyroid conditions, enabling clinicians to make more informed, precise decisions in patient care,” noted Frederik Bender, the chief executive officer of Piur Imaging.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.